|
Summative outcomes: The proportion of patients with current LDL-c measurements and patients prescribed lipid lowering medications from baseline to the end of intervention period |
|||||||
| Intervention versus Comparison |
Individual Intervention Sites |
Individual Comparison Sites |
|||||
|
|
|||||||
| Intervention |
Site A |
Site B |
Site C |
Site D |
Site E |
Site F |
|
|
|
|||||||
| Odds ratio for change from baseline to end of intervention without adjusting for degree of implementation (95% confidence intervals)* |
|||||||
|
|
|||||||
| Effect on proportion of patients with current LDL-c from baseline to end of intervention period¶ |
1.96 (1.34,2.88) |
1.45 (1.38,1.52) |
1.57 (1.44,1.72) |
1.64 (1.53,1.75) |
0.57 (0.50,0.66) |
0.67 (0.65,0.68) |
Reference |
| Effect on proportion of patients on lipid-lowering medications from baseline to intervention period¶ |
0.92 (0.72,1.19) |
0.89 (0.87,0.91) |
1.10 (1.01,1.20) |
0.54 (0.53,0.56) |
1.30 (1.07,1.57) |
0.68 (0.66,0.71) |
Reference |
|
|
|||||||
| Odds ratio for change from baseline to end of intervention adjusting for provider self-reported amount of use of IHD reminder (95% CI) |
|||||||
|
|
|||||||
| Effect on proportion of patients with current LDL-c from baseline to end of intervention period |
2.35 (1.96,2.81) |
1.33 (0.93,1.89) |
1.77 (1.11,2.82) |
1.46 (0.77,2.76) |
0.34 (0.27,0.43) |
0.58 (0.45,0.75) |
Reference |
| Effect on proportion of patients on lipid-lowering medications from baseline to intervention period |
0.87 (0.67,1.13) |
0.85 (0.71,1.03) |
1.05 (0.82,1.35) |
0.46 (0.34,0.61) |
1.35 (0.97,1.90) |
0.66 (0.59,0.75) |
Reference |
|
*Adjusted for patient baseline and facility characteristics in Table 2; odds ratios significant at p < 0.05 bolded §Intra-class correlation for measurement change was 0.08, 95% CI 0.00 – 0.18 ¶Intra-class correlation for treatment change was 0.02, 95% CI 0.00 – 0.05 | |||||||
Sales et al. Implementation Science 2008 3:28 doi:10.1186/1748-5908-3-28 |
|||||||